Evidence map›Paper›PMID 42063233›Full record

ArticleInternational journal of laboratory hematology2026

Role of Flow Cytometric Enumeration of Circulating hMICL (CD371) Positive Leukemic Stem Cells in Diagnosis and Prognostication of BCR::ABL1-Negative Myeloproliferative Neoplasms.

Gurleen Oberoi, Rishi Dhawan, Jasmita Dass, Neha Ganju, Ganesh Viswanathan, Suman Lata, Mukul Agarwal, Pradeep Kumar Kumar, Tulika Seth, Manoranjan Mahapatra and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of laboratory hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Gurleen OberoiDepartment of Hematology, All India Institute of Medical Sciences, New Delhi, India.ORCID https://orcid.org/0000-0003-2913-5171
Rishi DhawanDepartment of Hematology, All India Institute of Medical Sciences, New Delhi, India.
Jasmita DassDepartment of Hematology, All India Institute of Medical Sciences, New Delhi, India.ORCID https://orcid.org/0000-0001-8282-7842
Neha GanjuDepartment of Hematology, All India Institute of Medical Sciences, New Delhi, India.
Ganesh ViswanathanDepartment of Hematology, All India Institute of Medical Sciences, New Delhi, India.ORCID https://orcid.org/0000-0003-4793-6829
Suman LataDepartment of Hematology, All India Institute of Medical Sciences, New Delhi, India.
Mukul AgarwalDepartment of Hematology, All India Institute of Medical Sciences, New Delhi, India.ORCID https://orcid.org/0000-0002-9885-1625
Pradeep Kumar KumarDepartment of Hematology, All India Institute of Medical Sciences, New Delhi, India.
Tulika SethDepartment of Hematology, All India Institute of Medical Sciences, New Delhi, India.
Manoranjan MahapatraDepartment of Hematology, All India Institute of Medical Sciences, New Delhi, India.
Renu SaxenaDepartment of Hematology, All India Institute of Medical Sciences, New Delhi, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBCR-ABL1-negative myeloproliferative neoplasms (MPNs) often exhibit overlapping clinical and morphological features, making accurate subcategorization challenging. The h-MICL (CD371) antigen, selectively expressed on leukemic stem cells (LSCs) and absent on CD34

objectivesThis study aimed to evaluate the diagnostic utility of circulating CD34

methodsFifty-four patients with BCR-ABL1-negative MPNs were prospectively enrolled at a tertiary care center in North India over 18 months. Peripheral blood was analyzed via flow cytometry to quantify CD34

resultsA significant increase in circulating CD34

conclusionCirculating CD34

Indexed as

Antigens, CDFlow CytometryFusion Proteins, bcr-ablMyeloproliferative DisordersNeoplastic Stem CellsAdultAgedAntigens, CD34Biomarkers, TumorFemaleHumansMaleMiddle AgedPrognosisAntigens, CDAntigens, CD34Biomarkers, TumorFusion Proteins, bcr-abldiagnosisflow cytometrymyeloproliferative neoplasm (MPN)prognosissubclassification

Identifiers

PMID42063233
PMCPMC13555146

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.